Maharashtra to divert 3 lakh Covaxin doses for 18 to 44 age group to those above 45 due to shortage

State Health Minister Rajesh Tope also said over five lakh people above 45 years are awaiting the second dose of Covaxin in Maharashtra

Press Trust of India May 11, 2021 18:51:43 IST
Maharashtra to divert 3 lakh Covaxin doses for 18 to 44 age group to those above 45 due to shortage

Representational image. PTI

Mumbai: Amid a shortage of COVID-19 vaccine does, the Maharashtra government on Tuesday decided to divert three lakh vials of Covaxin meant for the 18-44 age group for the use of the people aged 45 years and above.

Speaking to reporters, state Health Minister Rajesh Tope also said more than five lakh people above 45 years are awaiting the second dose for the want of the vaccine.

"Efficacy of the vaccine is largely affected if the second dose is not administered in a stipulated time. To avoid such health crisis, the state government has decided to divert three lakh vials (of Covaxin) purchased for the 18-44 age category for the people above 45 years," Tope said.

He said only 35,000 vials of Covaxin are currently available with the state government for administering the second dose to people above 45 years.

According to the Liberalised Pricing and Accelerated National COVID-19 Vaccination Strategy, COVID-19 vaccination is free at government vaccination centres that receive doses from the Centre for eligible population groups comprising healthcare workers, frontline workers and people above the 45 years of age.

However, states and private hospitals have to procure 50 percent of the vaccines in order to immunise persons in the age group of 18 to 44 years.

Updated Date:

also read

Coronavirus News Updates: Maharashtra's COVID-19 toll tops one lakh with 233 fresh deaths; state sees 12,557 new cases
India

Coronavirus News Updates: Maharashtra's COVID-19 toll tops one lakh with 233 fresh deaths; state sees 12,557 new cases

Coronavirus News Updates: The recovery rate is now 95.05 percent and the fatality rate is 1.72 percent and there are 1,85,527 active cases

SII may roll out Novavax's Covovax COVID-19 vaccine by Sept; key updates on India's vaccine drive
India

SII may roll out Novavax's Covovax COVID-19 vaccine by Sept; key updates on India's vaccine drive

Novavax said that the efficacy of its vaccine was 93.2 percent against Variants of Concern (VoC) and Variants of Interest (VoI), which represented 82 percent of the cases during trials

Covishield dose gap row: Harsh Vardhan says decision was taken unanimously; calls controversy 'unfortunate'
India

Covishield dose gap row: Harsh Vardhan says decision was taken unanimously; calls controversy 'unfortunate'

Covishield dose gap row: Union health minister Harsh Vardhan too said the decision to increase the gap “has been taken in a transparent manner based on scientific data”